# To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

> **NCT05075408** · PHASE2,PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 258 (actual)

## Conditions studied

- Chronic Kidney Disease Associated Moderate to Severe Pruritus

## Interventions

- **DRUG:** Nemolizumab
- **DRUG:** Nemolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05075408
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-18
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-01-04
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075408, "To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05075408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*